// App-Quantinova.ai

: Long-term Safety and Efficacy of Difelikefalin in Patients With Chronic Kidney Disease?Associated Pruritus: Analysis From KALM-1 and KALM-2

Researchers

Presenter

  • Steven Fishbane

Principal Investigators

  • Warren Wen

  • Catherine Munera

  • Frederique Menzaghi

  • Kieran McCafferty

Medical Centers

  • Internal Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, NY, United States.

  • Cara Therapeutics, Stamford, CT, United States

  • Paediatrics, Royal London Hospital Barts Health NHS Trust, London,United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

Disease

  • Uraemic pruritus

Biomarkers

  • N/A

Drug/Treatment

  • Difelikefalin

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Cara Therapeutics

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved